Evidence map›Paper›PMID 41618417›Full record

ArticleJournal of nanobiotechnology2026

Glutathione responsive iNOS inhibiting polymeric prodrug for targeted Inhibition of angiogenesis.

Houman Alimoradi, Anita Fallah, Pascale Jespers, Nargis Bolaky, Françoise Gregoire, Helen Townley, Susanna Törnroth-Horsefield, Armin Shavandi, Laurence Dewachter, Christine Delporte

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Houman AlimoradiLaboratory of Pathophysiological and Nutritional Biochemistry (LPNB), Faculty of Medicine, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP 611, Brussels, 1070, Belgium. houman.alimoradi@ulb.be.
Anita FallahLaboratory of Pathophysiological and Nutritional Biochemistry (LPNB), Faculty of Medicine, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP 611, Brussels, 1070, Belgium.
Pascale JespersExperimental Laboratory of Intensive Care, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP604, Brussels, 1070, Belgium.
Nargis BolakyLaboratory of Pathophysiological and Nutritional Biochemistry (LPNB), Faculty of Medicine, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP 611, Brussels, 1070, Belgium.
Françoise GregoireLaboratory of Pathophysiological and Nutritional Biochemistry (LPNB), Faculty of Medicine, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP 611, Brussels, 1070, Belgium.
Helen TownleyNuffield Department of Women's and Reproductive Health, Medical Sciences Division, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.
Susanna Törnroth-HorsefieldDivision of Biochemistry and Structural Biology, Lund University, Box 124, Lund, 221 00, Sweden.
Armin Shavandi3BIO-BioMatter, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50 - CP 165/61, Brussels, 1050, Belgium.
Laurence DewachterExperimental Laboratory of Intensive Care, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP604, Brussels, 1070, Belgium.
Christine DelporteLaboratory of Pathophysiological and Nutritional Biochemistry (LPNB), Faculty of Medicine, Université Libre de Bruxelles, 808 Route de Lennik, Blg G/E CP 611, Brussels, 1070, Belgium. christine.delporte@ulb.be.

Funding

European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No 101034324
6 · The paper itself

Abstract

backgroundInducible nitric oxide synthase (iNOS) is a key driver of aberrant angiogenesis in inflammatory conditions and cancer, making it an attractive therapeutic target. Nevertheless, its function can be affected by the complex immune responses and tumor microenvironment (TME). Hence, combinatorial treatment approaches that simultaneously target iNOS and immune-modulatory signaling are strongly recommended for cancer therapy. Moreover, the current iNOS inhibitors are limited by poor pharmacokinetics and a lack of selectivity.

resultsTo address these challenges, we developed a glutathione (GSH)-responsive iNOS-inhibiting polymeric prodrug (GRIP) decorated with betamethasone succinate (NP

conclusionsThis is the first report of a GSH-responsive polymeric prodrug system that leverages intracellular GSH for both controlled release of anionic therapeutic agents and in situ synthesis of an iNOS antagonist. Through these two complementary pathways, the system enables targeted, sustained anti-angiogenic effects and promotes vascular normalization. This dual-function platform holds strong potential for the treatment of cancer-associated angiogenesis.

Indexed as

AngiogenesisAngiogenesis InhibitorsGlutathioneNitric Oxide Synthase Type IIPolymersProdrugsAnimalsBetamethasoneCell MovementHumansHuman Umbilical Vein Endothelial CellsMiceNanoparticlesNeovascularization, PathologicNitric OxideRatsAngiogenesis InhibitorsBetamethasoneGlutathioneNitric OxideNitric Oxide Synthase Type IIPolymersProdrugsVascular Endothelial Growth Factor AAngiogenesisGluthatione-responsive prodrugiNOSNitric oxideTumor microenvironment

Identifiers

PMID41618417
PMCPMC12934088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.